Bosko Andjelic
Overview
Explore the profile of Bosko Andjelic including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jelicic J, Larsen T, Andjelic B, Juul-Jensen K, Bukumiric Z
Crit Rev Oncol Hematol
. 2024 Feb;
196:104293.
PMID: 38346460
Models based on risk stratification are increasingly reported for Diffuse large B cell lymphoma (DLBCL). Due to a rising interest in nomograms for cancer patients, we aimed to review and...
2.
Jelicic J, Larsen T, Fialla A, Bukumiric Z, Andjelic B
Clin Lymphoma Myeloma Leuk
. 2022 Aug;
22(11):e981-e991.
PMID: 35948478
Over the years, a rising incidence of liver cirrhosis and lymphoma has been observed. Therefore, the risk of having cirrhosis as a comorbidity increases, thus challenging treatment approaches as data...
3.
Jelicic J, Larsen T, Bukumiric Z, Andjelic B
Crit Rev Oncol Hematol
. 2021 Jul;
164:103418.
PMID: 34246773
The Follicular Lymphoma International Prognostic Index (FLIPI) is widely used for risk stratification of patients with follicular lymphoma (FL). Motivated by evolvement in treatment modalities, several prognostic models for FL...
4.
Jelicic J, Larsen T, Bukumiric Z, Juul-Jensen K, Andjelic B
Crit Rev Oncol Hematol
. 2021 Apr;
161:103341.
PMID: 33865995
Over the last decade, several prognostic models have been proposed for primary central nervous system lymphoma (PCNSL), but consensus on the optimal model for these patients is absent or lacking....
5.
Jelicic J, Larsen T, Frederiksen H, Andjelic B, Maksimovic M, Bukumiric Z
Clin Epidemiol
. 2020 Jun;
12:537-555.
PMID: 32581596
Background And Aim: Based on advances in the diagnosis, classification, and management of diffuse large B-cell lymphoma (DLBCL), a number of new prognostic models have been proposed. The aim of...
6.
Antic D, Jelicic J, Trajkovic G, Todorovic Balint M, Bila J, Markovic O, et al.
Ann Hematol
. 2017 Nov;
97(2):267-276.
PMID: 29130134
The prognostic value of the International Prognostic Index (IPI) has been re-evaluated in the rituximab-treated diffuse large B cell lymphoma (DLBCL) patients. Accordingly, National Comprehensive Cancer Network-IPI (NCCN-IPI) has been...
7.
Markovic O, Andjelic B, Tarabar O, Todorovic M, Filipovic B, Stanisavljevic D, et al.
J BUON
. 2017 May;
22(2):481-486.
PMID: 28534373
Purpose: The purpose of this study was to evaluate the clinical characteristics, prognostic factors, therapy and outcomes of patients with very late relapse (>5 years) of Hodgkin's lymphoma (HL). Methods:...
8.
Mihaljevic B, Jelicic J, Andjelic B, Antic D, Markovic O, Petkovic I, et al.
Int J Hematol
. 2016 Oct;
104(6):692-699.
PMID: 27714586
The Follicular Lymphoma International Prognostic Index (FLIPI) is widely used in the identification of risk groups among follicular lymphoma (FL) patients. The aim of the present study was to evaluate...
9.
Antic D, Milic N, Nikolovski S, Todorovic M, Bila J, Djurdjevic P, et al.
Am J Hematol
. 2016 Jul;
91(10):1014-9.
PMID: 27380861
Lymphoma patients are at increased risk of thromboembolic events but thromboprophylaxis in these patients is largely underused. We sought to develop and validate a simple model, based on individual clinical...
10.
Todorovic Balint M, Jelicic J, Mihaljevic B, Kostic J, Stanic B, Balint B, et al.
Int J Mol Sci
. 2016 May;
17(5).
PMID: 27164089
The existence of a potential primary central nervous system lymphoma-specific genomic signature that differs from the systemic form of diffuse large B cell lymphoma (DLBCL) has been suggested, but is...